论文部分内容阅读
目的:观察阿托伐他汀钙对高血压合并高脂血症及超敏C-反应蛋白的影响。方法:对76例高血压病合并高血脂症患者,在常规降压治疗基础上加服阿托伐他汀钙10mg,1次/d,睡前服用,检测用药前后4周研究对象血脂、超敏C-反应蛋白、血压等因素的变化。结果:高血压病合并高脂血症患者经调脂和降压治疗后,血脂与血压显著下降(P<0.05),超敏C-反应蛋白水平显著下降(P<0.05)。结论:阿托伐他汀钙可明显降低高血压病合并高脂血症患者超敏C-反应蛋白水平,从而可能改善高血压病合并高脂血症患者的炎症状态,减缓动脉粥样硬化的形成。
Objective: To observe the effect of atorvastatin calcium on hypertension with hyperlipidemia and hypersensitivity C-reactive protein. Methods: A total of 76 hypertensive patients with hypertension and hyperlipidemia were treated with atorvastatin calcium 10 mg once daily on the basis of conventional antihypertensive treatment. The serum lipid and hypersensitivity were measured at 4 weeks before and after treatment C-reactive protein, blood pressure and other factors. Results: The levels of blood lipids and blood pressure decreased significantly (P <0.05) and the levels of hypersensitivity C-reactive protein (P <0.05) after hyperlipidemia and antihypertensive treatment in hypertensive patients with hyperlipidemia. Conclusions: Atorvastatin calcium can significantly decrease the level of hypersensitivity C-reactive protein in hypertensive patients with hyperlipidemia, which may improve the inflammatory state and reduce the formation of atherosclerosis in hypertensive patients with hyperlipidemia .